MNG402
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.560
- E2F_TARGETS+0.543
- MYC_TARGETS_V2+0.518
- MYC_TARGETS_V1+0.429
- MITOTIC_SPINDLE+0.397
- UNFOLDED_PROTEIN_RESPONSE+0.354
- MTORC1_SIGNALING+0.332
- UV_RESPONSE_UP+0.332
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- ANGIOGENESIS+0.298
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.342
- HEME_METABOLISM-0.201
- ADIPOGENESIS-0.110
- INTERFERON_GAMMA_RESPONSE-0.108
- KRAS_SIGNALING_DN-0.099
- PEROXISOME-0.074
- HYPOXIA-0.068
- XENOBIOTIC_METABOLISM-0.039
- COAGULATION-0.027
- MYOGENESIS-0.024
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFR3-TTP1-A-2-1-R-A743-41 | — | C | 0.851 |
| 2 | TCGA-A2-A0D2-01A-21R-A034-07 | — | E | 0.828 |
| 3 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.822 |
| 4 | BS_23QW0BBA | high-grade glioma | — | 0.817 |
| 5 | BS_9XVACXP0 | high-grade glioma | — | 0.814 |
| 6 | SRR934852 | — | — | 0.805 |
| 7 | MNG1064 | — | — | 0.805 |
| 8 | MNG308 | — | — | 0.803 |
| 9 | 8ACC0F29-A39E-4C1C-A04C-ED6E5FA80C24 | — | — | 0.803 |
| 10 | SRR10900569 | — | — | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.543 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.518 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.429 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.397 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.354 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.332 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.332 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.298 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.298 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.238 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.235 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.212 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.212 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.146 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.125 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.116 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.116 | Inavolisib | — uncovered |
| COMPLEMENT | 0.115 | Inavolisib | — uncovered |